Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RXI Group
Marlborough, Massachusetts, United Statesrxi.com.au ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Commercial
01
Overview
RXi developed a proprietary self-delivering RNA interference technology for targeted gene silencing. Lead program RXI‑109 targeting CTGF advanced to Phase II for dermal scarring. The company also pursued immuno-oncology applications with sd-rxRNA compounds. In 2018 it rebranded to Phio Pharmaceuticals to reflect its focus on next-generation immunotherapies using this platform. Clinical results showed proof-of-concept for local gene silencing with favorable safety profiles in initial studies; further data are under development or pending publication.
- Therapeutic areas
- OncologyDermatologyOphthalmology
- Modalities
- RNA therapySmall interfering RNAAntisense oligonucleotide
- Industry
- Biotech
02
Partnerships
OPKO Health and Frost Gamma Investments TrustTriLink BiotechnologiesUniversity of Massachusetts Medical SchoolCarnegie Institution of WashingtonGenentech (via Galena Biopharma division pre-split)
Beyond the preview
Go deeper on RXI Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RXI Group.